VivaScope Technology Enables Faster Diagnoses in Innovative Kidney Clinic in Cambridge
Munich / Cambridge, March 10, 2026 – VivaScope GmbH, a leading provider of confocal imaging systems for digital pathology, marks an important milestone for the future of rapid cancer diagnostics. At the “one-stop” kidney clinic at Addenbrooke’s Hospital in Cambridge, the VivaScope 2500 confocal microscope is now being used to assess biopsy samples directly on site, enabling clinicians to obtain diagnostic insights within minutes. Early results demonstrate a remarkable 91.7% concordance between diagnoses made using the confocal microscope and the final pathology results.
The innovative clinical model allows patients with suspected kidney cancer to undergo biopsy and receive an initial diagnosis during the same clinical visit. For many patients, this means that discussions about treatment options can take place immediately, significantly reducing the uncertainty and stress associated with long waiting periods. The initiative represents a “UK first” in rapid kidney cancer diagnostics and reflects a growing shift toward more patient-centered and efficient diagnostic pathways.
Traditionally, the analysis of biopsy samples can take several days or even weeks, as tissue needs to be processed, stained, and examined in specialized pathology laboratories. The VivaScope 2500 system uses confocal laser scanning microscopy to generate high-resolution digital images of fresh tissue samples without the need for extensive preparation. These images closely resemble traditional hematoxylin and eosin (H&E) stained slides, enabling pathologists to interpret them quickly and reliably.
The impact on patient care is significant. At Cambridge University Hospitals NHS Foundation Trust, which operates Addenbrooke’s Hospital, the introduction of the technology has helped reduce the average waiting time for kidney cancer patients by more than half—shortening the diagnostic timeline by approximately one month. Faster diagnosis not only accelerates clinical decision-making but also allows patients to begin appropriate treatment sooner.
“The results from Cambridge clearly demonstrate the potential of Instant Digital Pathology,” the company states. “Our mission is to support clinicians with technologies that enable faster, high-quality diagnostic insights directly at the point of care. The implementation at the kidney clinic highlights how confocal imaging can streamline clinical workflows while maintaining diagnostic confidence.”
The VivaScope 2500 is designed for scanning fresh biopsy samples, while the tissue remains intact and can still be used for conventional histopathological or molecular analyses afterwards.
With 50+ systems installed worldwide, VivaScope continues to advance the field of digital pathology. The successful application of the technology in Cambridge illustrates how innovative imaging solutions can transform diagnostic processes and ultimately improve outcomes for cancer patients.
Read the Article at BBC:
